Skip to main content

Russia Covid-19 vaccine: Over 250 people in Moscow get inoculated

By Unknown

The Russian government on Monday said that over 250 Moscow residents have got the dose of its first Covid-19 vaccine, Sputnik V, over the past five days, according to a report.

The vast majority of them are in good health, the anti-coronavirus crisis centre told reporters today.

"Over the past five days of clinical trials of the vaccine against the coronavirus infection over 250 Moscow residents got inoculated at the seven centres that opened first. Doctors closely monitor the health condition of the vaccinated. The absolute majority is in excellent health - 75% of the participants today do not observe any symptoms or ailments," the crisis centre said, according to the Russian news agency.

On Friday, Russian Health Minister Mikhail Murashko told reporters that the first batch of Russia's Covid-19 vaccine was likely to be delivered to all regions of the country by 14 September, according to TASS.

"The first batches of the vaccine for testing the supply chain have already been shipped, we are now checking the delivery system so that the staff gets to know it. The first small batches have already been shipped to all regions, the Leningrad region will also receive [the vaccine] among the first ones. In fact, the first samples of the vaccine will be delivered by Monday," Murashko had said.

The development comes after a week of Russia releasing the first batch of the Sputnik V vaccine into civil circulation, the Russian Health Ministry informed.

Sputnik V Covid vaccine, which is developed by Gamaleya Research Institute of Epidemiology and Microbiology under the Russian Health Ministry, may be granted permission to release a batch of its vaccine for civilian use, the institute’s deputy director for research, associate member of the Russian Academy of Sciences, Denis Logunov said earlier, according to a report.


Russia Covid-19 vaccine: Over 250 people in Moscow get inoculated, says report


Russian Sputnik V covid vaccine is undergoing Phase 3 trials

Russia Covid-19 vaccine: Over 250 people in Moscow get inoculated, says report

The vast majority of them are in good health, the anti-coronavirus crisis centre says

The development comes after a week of Russia releasing the first batch of the Sputnik V vaccine into civil circulation


Topics

Coronavirus Vaccine TrackerCovid-19Sputnik VRussia

The Russian government on Monday said that over 250 Moscow residents have got the dose of its first Covid-19 vaccine, Sputnik V, over the past five days, according to a report.

The vast majority of them are in good health, the anti-coronavirus crisis centre told reporters today.

"Over the past five days of clinical trials of the vaccine against the coronavirus infection over 250 Moscow residents got inoculated at the seven centres that opened first. Doctors closely monitor the health condition of the vaccinated. The absolute majority is in excellent health - 75% of the participants today do not observe any symptoms or ailments," the crisis centre said, according to the Russian news agency.

On Friday, Russian Health Minister Mikhail Murashko told reporters that the first batch of Russia's Covid-19 vaccine was likely to be delivered to all regions of the country by 14 September, according to TASS.

"The first batches of the vaccine for testing the supply chain have already been shipped, we are now checking the delivery system so that the staff gets to know it. The first small batches have already been shipped to all regions, the Leningrad region will also receive [the vaccine] among the first ones. In fact, the first samples of the vaccine will be delivered by Monday," Murashko had said.

The development comes after a week of Russia releasing the first batch of the Sputnik V vaccine into civil circulation, the Russian Health Ministry informed.

Sputnik V Covid vaccine, which is developed by Gamaleya Research Institute of Epidemiology and Microbiology under the Russian Health Ministry, may be granted permission to release a batch of its vaccine for civilian use, the institute’s deputy director for research, associate member of the Russian Academy of Sciences, Denis Logunov said earlier, according to a report.

On August 11, Russia became the first country to license a Covid-19 vaccine, calling it "Sputnik V" in homage to the world's first satellite, launched by the Soviet Union. But western experts have warned against its use until all internationally approved testing and regulatory steps have been taken. The vaccine is undergoing Phase 3 trials.

The vaccine produced an antibody response in all participants in early-stage trials, according to results published by The Lancet medical journal earlier that were hailed by Moscow as an answer to its critics.

The results of the two trials, conducted in June-July this year and involving 76 participants, showed 100% of participants developing antibodies to the new coronavirus and no serious side effects, The Lancet said.

However, a group of international scientists questioned results from the Lancet medical journal, saying some of the findings appeared improbable, reported Bloomberg.

The researchers flagged concerns over seemingly identical levels of antibodies in a number of study participants who were inoculated with the experimental vaccine. This and other patterns in the data present “several different points of concern," according to an open letter written by Temple University professor Enrico Bucci and signed by more than a dozen other scientists.


Comments

Post a Comment

Popular posts from this blog

Increased risks of drop out for women and girls : CoronaVirus Updates

By Unknown
The total number of children not returning to their education after the school closures is likely to be significant. The pandemic also risks jeopardizing some of the gains made since 2001 in re-building women and girls’ education following the Taliban regime.  The COVID-19 pandemic is creating additional barriers due to risks—and students’ and parents’ anxiety about risks—associated with children returning to classrooms that are cramped, with no capacity for distancing, often cold, damp and poorly ventilated during the country’s severe winters, and have no or poor hygiene and clean water facilities. The COVID-19 pandemic is likely to drive many women and girls out of education permanently. School closures due to COVID-19, resulting increases in caregiving responsibilities for women and girls, and increases in poverty and unemployment will all make it harder for women and girls to study.  These factors combine in harmful ways with pre-existing discriminatory gender norms, o...
Post a Comment
Read more

Glenmark's antiviral combination for moderate Covid-19 shows no clinical benefit

By Unknown
Glenmark Pharmaceuticals Ltd on Friday said addition of Umifenovir did not demonstrate any additional benefit over Favipiravir alone in moderate Covid-19 patients. Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment, the trial did not meet key end-points,  the company said. The trial's findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes, Monika Tandon, senior vice president & head, Clinical Development, Global Specialty/Branded Portfolio at the company, said in a statement , adding that favipiravir alone remains the effective choice for mild to moderate COVID-19 infection. Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014, while Umifenovir is licensed as a treatment for some types of flu infections in Russia and China. Fujifilm last month said a late-stage study of Avigan showed i...
Post a Comment
Read more

No significant benefit of Umifenovir in COVID-19 treatment: Glenmark

By Unknown
Drug firm  Glenmark Pharmaceuticals  on Friday said the addition of  antiviral Umifenovir  did not demonstrate any significant clinical benefit over  Favipiravir  alone in  moderate COVID-19 patients .  The  clinical study  evaluated the possible superiority of the combination's efficacy against Favipiravir monotherapy, Glenmark said in a statement. As per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir, it added. This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir, Glenmark said. "These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-1...
Post a Comment
Read more